| Cash and cash equivalents | |
| Marketable securities | |
| Prepaid expenses and other current assets | |
| Total current assets | |
| Property and equipment, net | |
| Restricted cash | |
| Other assets | |
| Total assets | |
| Accounts payable | |
| Accrued clinical trial expenses | |
| Other accrued expenses | |
| Deferred revenue | |
| Current portion of contingent consideration liability | |
| Financing obligations | |
| Total current liabilities | |
| Deferred rent | |
| Noncurrent portion of contingent consideration liability | |
| Preferred stock | |
| Common stock | |
| Additional paid-in-capital | |
| Other comprehensive income | |
| Deficit accumulated during development stage | |
| Total stockholders' equity | |
| Total liabilities and stockholders' equity |